"Depart from evil, and do good": Turning Axl from uncontrolled tumorigenic gene to biomarker for early detection of pancreatic cancer

Crit Rev Oncol Hematol. 2022 May:173:103659. doi: 10.1016/j.critrevonc.2022.103659. Epub 2022 Apr 6.

Abstract

Attempts to achieve early diagnosis are crucial to improve the outcome of patients with pancreatic ductal adenocarcinoma (PDAC). Here we present a critical evaluation of a recent study unraveling the potential of circulating AXL as a novel blood marker for early detection of PDAC and differential diagnosis from chronic pancreatitis (CP).

Keywords: AXL; Diagnosis; Liquid biopsies; Pancreatic cancer.

Publication types

  • Letter

MeSH terms

  • Biomarkers, Tumor / genetics
  • Carcinogenesis
  • Carcinoma, Pancreatic Ductal* / diagnosis
  • Carcinoma, Pancreatic Ductal* / genetics
  • Carcinoma, Pancreatic Ductal* / pathology
  • Early Detection of Cancer
  • Humans
  • Pancreatic Neoplasms* / diagnosis
  • Pancreatic Neoplasms* / genetics
  • Pancreatic Neoplasms* / pathology

Substances

  • Biomarkers, Tumor